Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Case Rep Gastroenterol ; 9(2): 188-93, 2015.
Article in English | MEDLINE | ID: mdl-26120300

ABSTRACT

Systemic mastocytosis (SM) is a rare, heterogeneous and progressive disease, characterized by the accumulation of atypical mast cells in various organs, including the gastrointestinal tract. Gastrointestinal symptoms are present in up to 80% of patients with SM, the most common being abdominal pain, diarrhea, nausea and vomiting. Up to 50% of patients with SM do not have classical skin lesions at presentation, and in these patients the diagnosis of SM can be difficult for years. Here we report a case of SM that initially mimicked inflammatory bowel disease, although the patient showed poor response to steroid therapy. The right diagnosis was made only on the surgical specimen obtained after emergency surgery for intestinal obstruction. SM should therefore be considered in the diagnostic approach in patients with gastrointestinal symptoms not attributable to other pathologies and in cases of suspected inflammatory bowel disease with unusual course.

2.
Liver Int ; 35(8): 2027-35, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25495478

ABSTRACT

BACKGROUND & AIMS: We elaborate a non-invasive score system for liver fibrosis (NISF), exploring its diagnostic performance and comparing its accuracy to FibroScan in patients with chronic viral hepatitis (CH) and non-alcoholic fatty liver disease (NAFLD). METHODS: Clinical, biochemical, elastographic and ultrasound parameters derived from patients with CH (n = 83) or NAFLD (n = 58), undergoing liver biopsy for fibrosis assessment, were prospectively collected as potential predictors of fibrosis. Each parameter was evaluated for its correlation with the liver biopsy (Gold Standard). Candidate predictors with good interobserver agreement and correlation with histological stages were combined into two algorithms (NISF) to predict fibrosis in chronic viral hepatitis and NAFLD. RESULTS: The CH-NISF included six parameters: bluntness of liver edges, irregularity of left lobe surface, diameter of segment 4, liver stiffness measurement, platelet count and ALT values. The ability of the model to discriminate F3-F4 vs F0-F1 stages and F2 vs F0-F1 was high (AUROC of 0.95 and 0.83 respectively) and better than FibroScan alone, especially in intermediate stages (F2 vs F0-F1), AUROC 0.83 vs 0.57 (P = 0.003). The resulting algorithm is available as mathematical formula, nomogram or free online link. [http://health.mafservizi.it/NISF_Calculator/liver.htm] The NAFLD-NISF included liver stiffness, platelet count and AST levels, had good ability to discriminate F0-F1 vs F2-F3-F4 stages (AUROC 0.86), however, not significantly higher than FibroScan. CONCLUSIONS: CH-NISF can be proposed as preliminary and easily available staging tool, superior to FibroScan alone in predicting histological fibrosis, especially in intermediate stages. Further validations are needed to improve NISF accuracy in NAFLD.


Subject(s)
Hepatitis, Viral, Human/diagnostic imaging , Hepatitis, Viral, Human/pathology , Non-alcoholic Fatty Liver Disease/diagnostic imaging , Non-alcoholic Fatty Liver Disease/pathology , Adult , Biopsy, Needle , Cohort Studies , Elasticity Imaging Techniques/methods , Female , Hepatitis B, Chronic/diagnostic imaging , Hepatitis B, Chronic/pathology , Hepatitis C, Chronic/diagnostic imaging , Hepatitis C, Chronic/pathology , Humans , Immunohistochemistry , Liver Cirrhosis/diagnostic imaging , Liver Cirrhosis/pathology , Male , Middle Aged , Predictive Value of Tests , ROC Curve , Sensitivity and Specificity , Severity of Illness Index , Ultrasonography, Doppler
3.
Cell Stress Chaperones ; 18(2): 235-41, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23073653

ABSTRACT

Levels of serum heat shock protein 27 (sHsp27) have been studied in numerous cancer types, but their potential relevance in patients with hepatocellular carcinoma (HCC) is undetermined. Our aim was to compare sHsp27 levels in patients with HCC and HCC-free controls. Specifically, we recruited 71 patients with HCC (80 % with early tumour), 80 patients with chronic liver disease (59 with liver cirrhosis and 21 with chronic active hepatitis) and 42 healthy subjects. sHsp27 was measured by immunoenzymatic assay. Results showed that sHsp27 levels were significantly (p < 0.001) higher in patients with HCC than in the other groups, particularly in those with hepatitis C virus (HCV)-related disease. In HCC patients, sHsp27 levels were not associated with prognostic risk factors, such as size/multiplicity of nodules and stage. In logistic regression analysis, performed in patients with liver disease, log-sHsp27 was associated with a significant age-adjusted 2.5-fold increased odds ratio of HCC and with a significant 4.4-fold higher odds ratio of HCC in the subgroup with HCV-related liver disease. In receiver operating characteristic curve analysis, sensitivity and specificity of the best sHsp27 cut-off value (456.5 pg/ml) for differentiating patients with HCC from those with HCC-free chronic liver disease were 70 and 73 %, respectively. In conclusion, sHsp27 levels are enhanced in patients with HCC and may represent a candidate biomarker of HCC.


Subject(s)
Carcinoma, Hepatocellular/blood , HSP27 Heat-Shock Proteins/blood , Liver Neoplasms/blood , Aged , Carcinoma, Hepatocellular/etiology , Carcinoma, Hepatocellular/pathology , Female , Hepatitis C/blood , Hepatitis C/complications , Hepatitis C/pathology , Humans , Liver Cirrhosis/blood , Liver Cirrhosis/pathology , Liver Diseases/blood , Liver Diseases/pathology , Liver Neoplasms/etiology , Liver Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Odds Ratio , Peptide Fragments/blood , Prognosis , Prothrombin , ROC Curve , Risk Factors , Severity of Illness Index , alpha-Fetoproteins/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...